Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
NASDAQ:TRDA
Price:
14.36 USD
2.21%
Market Closed
Updated:
May 10, 2024
Balance Sheet
Balance Sheet Decomposition
Entrada Therapeutics Inc
Entrada Therapeutics Inc
| Current Assets | 369.8m |
| Cash & Short-Term Investments | 352m |
| Receivables | 5.9m |
| Other Current Assets | 11.9m |
| Non-Current Assets | 99.4m |
| PP&E | 92.7m |
| Other Non-Current Assets | 6.7m |
| Current Liabilities | 158.8m |
| Accounts Payable | 3.3m |
| Accrued Liabilities | 19.2m |
| Other Current Liabilities | 136.3m |
| Non-Current Liabilities | 68m |
| Other Non-Current Liabilities | 68m |
Balance Sheet
Entrada Therapeutics Inc
Entrada Therapeutics Inc
Currency: USD
| Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
17
|
39
|
291
|
45
|
68
|
|
| Cash Equivalents |
17
|
39
|
291
|
45
|
68
|
|
| Short-Term Investments |
0
|
0
|
0
|
144
|
284
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
6
|
|
| Other Current Assets |
1
|
1
|
8
|
21
|
12
|
|
| Total Current Assets |
17
|
40
|
299
|
210
|
370
|
|
| PP&E Net |
1
|
3
|
6
|
33
|
93
|
|
| PP&E Gross |
1
|
3
|
6
|
33
|
93
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
3
|
6
|
|
| Other Long-Term Assets |
0
|
1
|
1
|
9
|
7
|
|
| Total Assets |
18
N/A
|
44
+139%
|
306
+603%
|
252
-18%
|
469
+86%
|
|
| Liabilities | ||||||
| Accounts Payable |
1
|
2
|
1
|
6
|
3
|
|
| Accrued Liabilities |
1
|
2
|
6
|
16
|
19
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
136
|
|
| Total Current Liabilities |
2
|
3
|
7
|
22
|
159
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
18
|
68
|
|
| Total Liabilities |
2
N/A
|
3
+79%
|
7
+109%
|
40
+456%
|
227
+474%
|
|
| Equity | ||||||
| Common Stock |
32
|
82
|
0
|
0
|
0
|
|
| Retained Earnings |
16
|
43
|
94
|
188
|
195
|
|
| Additional Paid In Capital |
1
|
1
|
392
|
403
|
437
|
|
| Other Equity |
0
|
0
|
0
|
2
|
0
|
|
| Total Equity |
16
N/A
|
40
+147%
|
299
+643%
|
213
-29%
|
242
+14%
|
|
| Total Liabilities & Equity |
18
N/A
|
44
+139%
|
306
+603%
|
252
-18%
|
469
+86%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
30
|
30
|
31
|
31
|
33
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
